JAMES HENDERSON: Open Payments
NPI 1780244608 · GADSDEN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$770 in 40 payments from 11 companies in 2025. Trend: 2023 $1,060 · 2024 $1,470 · 2025 $770
Food & beverage: $770
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $230 |
| ABBVIE INC. | 11 | $184 |
| Vanda Pharmaceuticals Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 2 | $33 |
| Corium, LLC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, FANAPT, REXULTI, Qelbree, Auvelity, SPRAVATO, Azstarys.
Industry payments across AL — which companies pay providers there.
